NCT00001953 - Clinical Trial References

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Citation(s)

Fox PC, Speight PM
Current concepts of autoimmune exocrinopathy: immunologic mechanisms in the salivary pathology of Sjögren's syndrome. Crit Rev Oral Biol Med. 1996;7(2):144-58. Review.
Fox RI, Törnwall J, Maruyama T, Stern M
Evolving concepts of diagnosis, pathogenesis, and therapy of Sjögren's syndrome. Curr Opin Rheumatol. 1998 Sep;10(5):446-56. Review.
Moutsopoulos HM, Manoussakis MN
Immunopathogenesis of Sjogren's syndrome: "facts and fancy". Autoimmunity. 1989;5(1-2):17-24. Review.

Basal and Stimulated Somatostatin Plasma Levels in Patients With Primary Sjogren's Syndrome and in Control Subjects

Clinical trial NCT00001953 - References